Viyash Scientific Ltd Share Price Today

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
UTI Healthcare Fund - Regular Plan - IDCW	8.42 Lac	8.42 Lac no change
Samco Multi Cap Fund - Regular Plan - Growth	43.67 k	- (100%)
Motilal Oswal Nifty Microcap 250 Index Fund - Regular Plan - Growth	4.03 Lac	- (100%)
Motilal Oswal BSE Healthcare ETF	4.19 k	- (100%)
Motilal Oswal BSE 1000 Index Fund - Regular Plan - Growth	454	- (100%)

DEEPAK PAL

7 Sep • 1:01 PM · SEBI-Registered Analyst

GROWING SEGMENT--> Pet Healthcare में बड़ा मौका या सिर्फ...?

Fredun Pharmaceuticals ने Pet & Animal Healthcare space में एक नया digital initiative “PAWTALKS” लॉन्च किया है। लेकिन यह सिर्फ एक Podcast नहीं है। कंपनी इसे एक knowledge-first platform के रूप में position कर रही है, जिसका उद्देश्य veterinary experts, researchers, pet parents, animal welfare advocates और industry leaders को एक साथ जोड़ना है। ----->PAWTALKS में क्या मिलेगा? Platform पर content कई महत्वपूर्ण topics को cover करेगा: • Veterinary Healthcare • Preventive Healthcare • Diagnostics • Pet Nutrition • Animal Behaviour • Emerging Veterinary Technologies • Animal Welfare PAWTALKS में क्या मिलेगा? Platform पर content कई महत्वपूर्ण topics को cover करेगा: • Veterinary Healthcare • Preventive Healthcare • Diagnostics • Pet Nutrition • Animal Behaviour • Emerging Veterinary Technologies • Animal Welfare ## Fredun के लिए यह क्यों महत्वपूर्ण है? Fredun पहले से ही Pet & Veterinary Healthcare business में मौजूद है। कंपनी की pet-health strategy में FREOSS products, veterinary care और pet diagnostics जैसे areas शामिल हैं। Fredun की FY25 annual report में भी pet care को future growth areas में शामिल किया गया था, जिसमें preventive pet health और direct consumer engagement पर जोर दिया गया था। इसलिए PAWTALKS को कंपनी की consumer-facing pet-care strategy के extension के रूप में देखा जा सकता है। @@FOCUS STOCKS Fredun Pharmaceuticals

VIYASH

AVANTI FEED ##Bottom Line Fredun Pharma सिर्फ Pet Medicines बेचने की कहानी नहीं बनना चाहती — वह पूरा Pet Healthcare Ecosystem बनाने की कोशिश कर रही है। PAWTALKS → Awareness Pet Community → Engagement Diagnostics + Nutrition + Veterinary Care → Products & Services

Vimal K

1 Jun • 8:30 AM · SEBI-Registered Analyst

STOCKS TO KEEP ON RADAR – DOUBLED REVENUE IN Q4 FY26

A company showing 100%+ sales growth sounds exciting and every results season produces a list of companies with dramatic growth numbers. The honest job of analysis is not to celebrate the list but to read it to understand why each company doubled its revenue, whether that growth is structural or transient and what the profit picture says about the quality of the expansion. Here are the list of companies with market capitalisation above Rs 10,000 crore that reported Q4 FY26 sales more than double their Q4 FY25 sales. Eternal, Jio Financial, Lloyds Metals, Waaree Energies, Multi Commodity Exchange, Prestige Estates, Motilal Oswal Financial, Tata Investment Corporation, SJVN, HFCL, Neuland Laboratories, IndiGrid Trust, Cupid, Thangamayil Jewellery, SignatureGlobal, Viyash Scientific, Lloyds Engineering.

ETERNAL

JIOFIN

WAAREEENER

MCX

Sunil Kotak

20 May • 8:27 AM · SEBI-Registered Analyst

Q4FY26 & FY26 Result Announced for Viyash Scientific Ltd.

VIYASH

Pharmaceuticals company Viyash Scientific announced Q4FY26 & FY26 results Consolidated Financial Highlights Revenue from Operations: Consolidated revenue for Q4FY26 was Rs 9,199.60 million, up 7.17% QoQ from Rs 8,584.10 million and up 19.12% YoY from Rs 7,723.10 million. For the full year FY26, revenue was Rs 34,203.10 million, an increase of 13.75% YoY from Rs 30,068.40 million in FY25. Total Income: Consolidated total income for Q4FY26 reached Rs 9,358.80 million, a growth of 7.28% QoQ and 19.59% YoY. Annual total income for FY26 stood at Rs 34,638.60 million compared to Rs 30,397.30 million in FY25. Profit Before Tax (PBT): Consolidated PBT for Q4FY26 was Rs 1,252.40 million, up 71.40% QoQ from Rs 730.70 million and a significant turnaround from a loss of Rs 366.60 million in Q4FY25. For the full year FY26, PBT grew to Rs 3,490.20 million from Rs 131.80 million in FY25. Net Profit After Tax (PAT): Consolidated net profit for Q4FY26 was Rs 663.80 million, up 36.81% QoQ from Rs 485.20 million and a turnaround from a loss of Rs 321.80 million in Q4FY25. For the full year FY26, consolidated PAT reached Rs 2,246.50 million, marking a massive increase from Rs 157.70 million in FY25. Total Comprehensive Income: Consolidated total comprehensive income for FY26 was Rs 3,315.50 million compared to Rs 308.00 million in FY25. Earnings Per Share (EPS): Consolidated basic EPS for FY26 grew to Rs 4.09 from Rs 0.54 in FY25. All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24

Prachi Mehta

23 Jan • 9:32 AM · SEBI-Registered Analyst

Stocks in news today

NTPCGREEN

(NGEL) has signed a Memorandum of Understanding (MoU) with Government of Uttar Pradesh for development of Renewable Energy and Green Hydrogen Projects in Uttar Pradesh.

STLTECH

(STL) has collaborated with Colt Technology Services (Colt) for the Multi-Core Fibre (MCF) trials executed across Colt’s London metro optical network in London, UK. This marks a significant milestone in real-world validation of MCF technology as a sustainable, high-capacity, cost-efficient backbone for next-generation networks supporting AI, cloud, and digital services.

ZAGGLE

(Zaggle) has entered into an agreement with HDFC ERGO General Insurance Company. Zaggle would provide HDFC Ergo General Insurance Company Limited, the Zaggle Propel reward platform. Simplex Castings has received a follow-up fabrication order worth Rs 7 crore from Bharat Heavy Electricals, Trichy for 900 MT of Fabrication and supply of Column, Auto Weld and General Fabrication for Mahagenco Koradi (Nagpur, Maharashtra) & Korba West (Korba, Chhattisgarh) Projects. The work shall be completed within 300 days from the issue of work or purchase order. Mach Conferences and Events has secured a large-scale MICE movement to Mumbai for around 1,600 participants. The project represents an approximate business value of Rs 8.45 crore and will be executed within the current financial year. Viyash Scientific’s wholly owned subsidiary -- Alivira Animal Health has entered into a partnership agreement with Boehringer Ingelheim India Private Limited for the distribution and promotion of their companion animal products portfolio in India. This partnership is designed to capture the growing opportunities in India’s pet healthcare market, driven by increased pet ownership, rising awareness of preventive care and growing emphasis on animal well-being across the country.

CA. Hardik Kachchava

19 Nov • 4:03 PM · SEBI-Registered Analyst

Sequent Scientific: Post-Merger Roadmap & Strategic Guidance

SEQUENT

Event Update Sequent Scientific has successfully received NCLT approval for its merger with Viyash Lifesciences. Following this development, the management, led by Group CEO Hari Babu, has unveiled a comprehensive strategic roadmap aimed at consolidating leadership in the Animal Health sector while leveraging Viyash’s capabilities in Human Health. Financial Guidance (FY27) Revenue Target: The combined entity projects a topline of ₹4,000 crore by FY27. Profitability: Management has guided for EBITDA margins to exceed 20%, driven by operational efficiencies and an improved product mix. Balance Sheet: The merged entity maintains a healthy leverage profile with a Net Debt-to-EBITDA ratio of 0.7x. As Viyash is nearly debt-free, the combined operating cash flows are expected to further accelerate deleveraging. Operational Synergies & Business Mix The merger creates a balanced revenue structure, mitigating segment concentration risk. Revenue Split: The combined entity will operate with a balanced 50:50 mix between APIs and Formulations. Complementary Strengths: Sequent: Dominance in Animal Health (65–70% Formulations). Viyash: Strength in Human Health (65% APIs), US Formulations, and emerging CDMO capabilities. Margin Profile: While Sequent’s margins have shown steady improvement over the last four quarters, Viyash’s Human Health portfolio currently contributes superior margins, enhancing the consolidated margin profile. Strategic Outlook Primary Focus: The core objective for the next five years is to establish the entity as a leading global player in Animal Health, with a specific focus on the high-growth pet care segment. Growth Phases: Near Term (1–3 Years): Steady, concurrent growth in both APIs and Formulations. Medium Term (Year 4+): Acceleration in Formulation revenue. Long Term (FY28 Onwards): Projected revival and expansion in the API cycle.

Shree Dhanraksha Securities

27 Sep • 1:58 PM · SEBI-Registered Analyst

*SeQuent Scientific's Strategic Merger*

Pharmaceutical firm SeQuent Scientific witnessed an 18% surge in its stock price after announcing a strategic merger with Viyash Life Sciences. This merger is expected to create a global leader in animal health, enhancing the company’s capabilities and attracting heavy trading volumes. The stock hit a three-year high in intraday trading.

Viyash Scientific Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Viyash Scientific Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Viyash Scientific Ltd.?

What is the market cap of Viyash Scientific Ltd.?

Should I buy Viyash Scientific Ltd. stock now?

What is the 52 week high and low of Viyash Scientific Ltd.?

Is the Viyash Scientific Ltd. stock good to buy?

Is Viyash Scientific Ltd. a good buy for the long term?

Is Viyash Scientific Ltd. overvalued or undervalued?

What is the PE and PB ratio of Viyash Scientific Ltd.?